4549
EIKEN CHEMICAL CO.,LTD.
栄研化学
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
38,667
Mar 2022
42,996
Mar 2023
43,271
Mar 2024
40,052
Mar 2025
40,539
Operating profit(million JPY)
Mar 2021
6,612
Mar 2022
8,387
Mar 2023
7,457
Mar 2024
3,377
Mar 2025
2,999
Operating profit margin(%)
Mar 2021
17.1
Mar 2022
19.51
Mar 2023
17.23
Mar 2024
8.43
Mar 2025
7.4
Profit before tax(million JPY)
Mar 2021
6,870
Mar 2022
8,482
Mar 2023
7,592
Mar 2024
3,503
Mar 2025
2,991
Profit(million JPY)
Mar 2021
5,044
Mar 2022
6,218
Mar 2023
5,736
Mar 2024
2,634
Mar 2025
2,228
Total assets(million JPY)
Mar 2021
55,685
Mar 2022
62,512
Mar 2023
66,275
Mar 2024
61,651
Mar 2025
62,372
Cash and cash equivalents(million JPY)
Mar 2021
6,968
Mar 2022
10,900
Mar 2023
16,064
Mar 2024
10,966
Mar 2025
7,640
Cash flows from operating activities(million JPY)
Mar 2021
5,451
Mar 2022
7,769
Mar 2023
7,575
Mar 2024
3,806
Mar 2025
6,033
Cash flows from investing activities(million JPY)
Mar 2021
-2,193
Mar 2022
-5,044
Mar 2023
-316
Mar 2024
-2,216
Mar 2025
-4,499
Cash flows from financing activities(million JPY)
Mar 2021
-1,275
Mar 2022
1,200
Mar 2023
-2,095
Mar 2024
-6,694
Mar 2025
-4,857
Return on equity(%)
Mar 2021
12.9
Mar 2022
14.3
Mar 2023
12.1
Mar 2024
5.6
Mar 2025
5
Equity ratio(%)
Mar 2021
74.3
Mar 2022
72.8
Mar 2023
74.2
Mar 2024
74
Mar 2025
69.3
Earnings per share(JPY per share)
Mar 2021
136.65
Mar 2022
168.28
Mar 2023
155.17
Mar 2024
71.69
Mar 2025
64.82
Net assets per share(JPY per share)
Mar 2021
1,120.36
Mar 2022
1,230.55
Mar 2023
1,327.47
Mar 2024
1,318.38
Mar 2025
1,294.08
Dividend per share(JPY per share)
Mar 2021
41
Mar 2022
51
Mar 2023
51
Mar 2024
51
Mar 2025
53
Payout ratio(%)
Mar 2021
30
Mar 2022
30.31
Mar 2023
32.87
Mar 2024
71.14
Mar 2025
81.76
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.